|Bid||27.10 x 4000|
|Ask||27.20 x 800|
|Day's Range||26.39 - 27.28|
|52 Week Range||12.56 - 27.28|
|Beta (3Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2019 - Aug 16, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.80|
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
The market may have popped on Tuesday, but it wasn't a terribly impressive move. The S&P 500's 0.85% gain still left it below some key technical lines, and the volume behind the gain was tepid.Source: Allan Ajifo via Wikimedia (Modified)Array Biopharma (NASDAQ:ARRY) was the big winner, gaining 23% following news that its colon cancer regimen met its endgoals in a late-stage trial. Among the more familiar, large and market-moving names though, the 2.5% gain Advanced Micro Devices (NASDAQ:AMD) logged was less thrilling though more noteworthy. The partial alleviation of trade tensions, particularly surrounding tech, released the hold that had stymied most of these names on Monday.At the other end of the spectrum, retailer Kohl's (NYSE:KSS) was crushed, losing more than 12% of its value on the heels of lousy Q1 print that forced the company to dial back its full-year profit forecast … weakness that wasn't necessarily mirrored by other retailers.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Small-Cap Stocks That Look Like Bargains None of those names are compelling trade prospects as we head into the midpoint of the week, however. Rather, it's the stock charts of TJX Companies (NYSE:TJX), Lamb Weston Holdings (NYSE:LW) and Oracle Corporation (NYSE:ORCL) that are worth the closest look. Here's that look. Oracle Corporation (ORCL)Oracle shares have dished out an impressive runup since late last year, and for the most part have sidestepped the recent market turbulence.Take a closer look at both stock charts, though, and it's clear that momentum is slowing. Indeed, it has stopped and it is teetering on a reversal back into a downtrend. One or two more rough days could put shares into a more pronounced selloff. Click to Enlarge * The most important line to watch now is the one that tags all the key lows going back early February. It's plotted in yellow on the daily chart. It's at $53.59 right now. * Although that floor is still intact, ORCL has already pulled below the purple 50-day moving average line a couple of different times. * Zooming out to the weekly chart of Oracle, all the key bearish clues are lining up. The RSI line only had to kiss the 70 level last month before starting to unwind, and we could see a bearish MACD cross before the end of the week. That latter event could spur some programmed selling. TJX Companies (TJX)In the middle of yesterday's trading session, TJX Companies shares looked like they were in real trouble. Already trending lower from a late-April peak, fresh pressure was being put on the white 200-day moving average line. Despite the earnings beat and raised outlook, traders saw matters through a bearish lens … right up until they didn't.By the end of the day, TJX shares were back in the black, having pushed up and off of the critical 200-day line. The big intraday swing backed by a clear volume surge suggesting a major turning of the tide. There's just one more hurdle for the bulls to clear, though it's a huge one. * 7 Safe Stocks to Buy for Anxious Investors Click to Enlarge * The big hurdle in question is actually the combination of the blue 20-day moving average line at $53.88 as well as the purple 50-day moving average line at $53.57. * The scope of the swing itself is telling, indicating a sweeping change of heart, prompted by news. Such reversals tend to go somewhere. * Almost just as likely, though, is a breakdown. Should the bears decide to retest the 200-day line at $51.49 (and the gray 100-day moving average line right below it at $51.18) and it fails to hold as a floor, the bearish momentum in place since late April could pile-drive the stock following a failed reversal. Lamb Weston Holdings (LW)Finally, when we last looked at Lamb Weston Holdings a month ago, we cautioned that while it had not yet broken below a major support line, the undertow was alarmingly bearish. The selling volume was picking up the pace as well.It turned out to be a worthy worry, though only for a few days. While LW stock edged its way back higher, it met a familiar technical ceiling to end up breaking under any of what could have been technical floors. A new one has been made in the meantime, but it's not great, and also starting to crumble. Click to Enlarge * The newest technical floor is right around $65.17, plotted in blue on the daily chart. That's more or less where Lamb Weston has found support since the beginning of the month. * Although there's a floor in play now, both of the more meaningful support lines plotted in red and yellow on both stock charts have been snapped. * It's easy to overlook, but the purple 50-day moving average line is now below the white 200-day moving average … a so-called "death cross" that suggests more selling is ahead. * It's only readily evident on the weekly chart, but with the break under the yellow "neckline," Lamb Weston appears to have just completed a bearish head-and-shoulders setup.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post 3 Big Stock Charts for Wednesday: Oracle, Lamb Weston Holdings and TJX Companies appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
Earnings, trial results, and acquisition activity were contributing factors to today's move higher for the stock market.
Shares jumped in Tuesday's session after favorable clinical trial results paved the way for potentially near-term marketing approval.
Array BioPharma Inc's cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study on Tuesday. The combination therapy, comprising Array's Braftovi and Mektovi and Eli Lilly and Co's Erbitux, helped half the patients enrolled in the study survive nine months. Array's combination also helped reduce the risk of death from colorectal cancer by 48% compared to the standard of care in patients, with a gene mutation known as BRAF V600E, whose cancer had progressed after one or two other therapies.
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be ...
Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
Pharmaceutical company Array BioPharma Inc. (NASDAQ: ARRY ) shares dipped more than 3 percent Thursday following comments from a sell-side analyst that investors may have to wait longer for results from ...
Array BioPharma (ARRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
BOULDER, Colo. , May 9, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2019 Health ...
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
Array BioPharma Inc. (Nasdaq: ARRY) saw its revenue decline year-over-year and posted a loss per share, but still beat analyst expectations. The company saw $35.1 million in U.S. net product sales for its drug combination Braftovi + Mektovi. The company is also seeing its combination of Braftovi + Mektovi with the drugs cetuximab or pantimumab recommended as a treatment option by the national Comprehensive Cancer Network for patients with a certain form of colorectal cancer.
Array BioPharma (ARRY) delivered earnings and revenue surprises of 19.05% and 25.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 17 cents. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...
Array Biopharma Inc NASDAQ NMS:ARRYView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ARRY with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.83 billion over the last one-month into ETFs that hold ARRY are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter - - BEACON CRC Phase 3 trial interim analysis remains on track to report out this ...
BOULDER, Colo. , April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results ...
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it right every time, but when you do, the returns can be truly splendid. Take, for example, the Array BioPharm...
The Insider Monkey team has completed processing the quarterly 13F filings for the December quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]